摘要
目的探讨CYP2C19基因多态性对胃溃疡患者抗Hp治疗的影响。方法采集Hp阳性的胃溃疡患者106例,随机分成埃索美拉唑(EAC)组和奥美拉唑(OAC)组,进行为期1w的抗Hp治疗。治疗4w后检测Hp根除情况及两组CYP2C19基因多态性,并分析CYP2C19基因多态性对抗Hp治疗效果的影响。结果 OAC组hom-EMs基因型的Hp根除率明显低于het-EMs和PMs,het-EMs和PMs比较差异无统计学意义。EAC组3种基因型hom-EMs、het-EMs、PMsHp根除率比较,差异无统计学意义。结论以奥美拉唑为基础的三联1w疗法Hp根除率与CYP2C19基因多态性有关,其中携带hom-EMs基因型根除率低;以埃索美拉唑为基础的三联1w疗法Hp根除率不受CYP2C19基因多态性影响。
Objective To study the influence of CYP2C19 polymorphism on anti-Hp treatment of patients with gastric ulcer （GU）. Methods A total of 106 GU patients with positive Hp were randomly divided into esomeprazole group （EAC group） and omeprazole group （OAC group）, and anti-Hp treatment was performed on these patients for one week. The Hp eradication and CYP2C19 gene polymorphism were detected four weeks after treatment. The influence of CYP2C19 polymorphism on the effects of Hp treatment was analyzed. Results The eradication rate of Hp with genotype hom-EMs was obviously lower than that with genotypes het-EMs and PMs in OAC group. Compared with genotypes het-EMs and PMs,the difference had statistical significance. However,there were no significant differences among the three genotypes in EAC group. Conclusion The eradication rate of Hp with esomeprazole-based triple therapy correlates with the polymorphism of CYP2C19, and the genotype hom-EMs is relate to the low eradication rate. However, the CYP2C19 gene polymorphism have nothing to do with the eradication rate of Hp when treated with esomeprazole-based triple therapy.
出处
《成都医学院学报》
CAS
2013年第3期310-312,共3页
Journal of Chengdu Medical College
基金
深圳市科技计划项目(NO:200602026)
